PURPOSE: In contrast to other human tumors, a repression of the cell-surface glycoprotein CD44 on neuroblastoma is a marker of aggressiveness that usually correlates to N-myc amplification. We thus compared the prognostic value of both markers in the initial staging of 121 children treated for neuroblastoma in collaborative institutions. METHODS: Frozen samples were analyzed by a rapid and well-standardized technique of immunostaining with monoclonal antibodies (MoAbs) against epitopes in the CD44 constant region. RESULTS: In this retrospective series, CD44 was expressed on 102 specimens and strongly correlated with favorable tumor stages and histology, younger age, and normal N-myc copy numbers. In univariate analysis, CD44 expression and normal N-myc were the most powerful markers of favorable clinical outcome (P < 10(-6) and chi 2 = 65.40 and P < 10(-6) and chi 2 = 42.56, respectively), but analysis of CD44 affords significant prognostic discrimination in subgroups of patients with or without N-myc-amplified tumors. In the subgroup of stage IV neuroblastomas, CD44 was the only significant prognostic marker (P < .02, chi 2 = 5.76), whereas N-myc status was not discriminant. In multivariate analysis of five factors, ie, N-myc amplification, CD44 expression, age, tumor stage, and histology, the only independent prognostic factors of event-free survival were CD44 expression and tumor stage. CONCLUSION: The analysis of CD44 cell-surface expression must be recommended as an additional biologic marker in the initial staging of the disease.
PURPOSE: In contrast to other humantumors, a repression of the cell-surface glycoprotein CD44 on neuroblastoma is a marker of aggressiveness that usually correlates to N-myc amplification. We thus compared the prognostic value of both markers in the initial staging of 121 children treated for neuroblastoma in collaborative institutions. METHODS: Frozen samples were analyzed by a rapid and well-standardized technique of immunostaining with monoclonal antibodies (MoAbs) against epitopes in the CD44 constant region. RESULTS: In this retrospective series, CD44 was expressed on 102 specimens and strongly correlated with favorable tumor stages and histology, younger age, and normal N-myc copy numbers. In univariate analysis, CD44 expression and normal N-myc were the most powerful markers of favorable clinical outcome (P < 10(-6) and chi 2 = 65.40 and P < 10(-6) and chi 2 = 42.56, respectively), but analysis of CD44 affords significant prognostic discrimination in subgroups of patients with or without N-myc-amplified tumors. In the subgroup of stage IV neuroblastomas, CD44 was the only significant prognostic marker (P < .02, chi 2 = 5.76), whereas N-myc status was not discriminant. In multivariate analysis of five factors, ie, N-myc amplification, CD44 expression, age, tumor stage, and histology, the only independent prognostic factors of event-free survival were CD44 expression and tumor stage. CONCLUSION: The analysis of CD44 cell-surface expression must be recommended as an additional biologic marker in the initial staging of the disease.
Authors: X X Tang; H Zhao; M E Robinson; B Cohen; A Cnaan; W London; S L Cohn; N K Cheung; G M Brodeur; A E Evans; N Ikegaki Journal: Proc Natl Acad Sci U S A Date: 2000-09-26 Impact factor: 11.205
Authors: Jun S Wei; Braden T Greer; Frank Westermann; Seth M Steinberg; Chang-Gue Son; Qing-Rong Chen; Craig C Whiteford; Sven Bilke; Alexei L Krasnoselsky; Nicola Cenacchi; Daniel Catchpoole; Frank Berthold; Manfred Schwab; Javed Khan Journal: Cancer Res Date: 2004-10-01 Impact factor: 12.701
Authors: V Combaret; N Gross; C Lasset; K Balmas; R Bouvier; D Frappaz; C Beretta-Brognara; T Philip; M C Favrot; J L Coll Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: H Ikeda; T Iehara; Y Tsuchida; M Kaneko; J Hata; H Naito; M Iwafuchi; N Ohnuma; H Mugishima; Y Toyoda; M Hamazaki; J Mimaya; S Kondo; K Kawa; A Okada; E Hiyama; S Suita; H Takamatsu Journal: Br J Cancer Date: 2002-04-08 Impact factor: 7.640